Millipore Corporation has unveiled a major expansion of its St. Charles, Missouri facility – headquarters for its Drug Discovery Business Unit.
The $3.4 million expansion will enable Millipore to keep pace with the growth of its worldwide drug discovery and development business, which provides products and services that help pharmaceutical and biotechnology companies discover, evaluate and develop drug candidates.
“The expansion of our St. Charles facility is a demonstration of our ongoing commitment to expanding our capabilities in the drug discovery market and investing in people and facilities that will help us deliver innovative products and services to our customers,” said Martin Madaus, Millipore Chairman, CEO and President.
“Through acquisition and internal growth, we have emerged as a major player in the drug discovery market and we are transforming into a life science leader.”
As part of that transformation, in 2006 Millipore acquired Serologicals Corporation – and with it, the former Linco Research business which was headquartered in St. Charles.
“Our expanded St. Charles facility will help us meet the needs of customers at every stage of the drug discovery and development pipeline – from target identification through clinical studies,” noted Rick Ryan, Vice President of Millipore’s Drug Discovery and Development Business Unit. ”It will also enable us to continue to expand our workforce in the greater St. Louis region.”
Millipore plans to hire an additional 60 employees at the St. Charles site, which currently employs 187 people.
Millipore is seeking LEED certification of the expanded and renovated 17,000-square-foot space, which is just one of Millipore’s three buildings on the 43-acre Missouri Research Park campus. The newly expanded and renovated space houses laboratories, administrative offices and an enlarged break area.